Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：59頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014’, provides an overview of the Uterine Leiomyoma (Uterine Fibroids)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Uterine Leiomyoma (Uterine Fibroids) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Uterine Leiomyoma (Uterine Fibroids) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uterine Leiomyoma (Uterine Fibroids) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014’, provides an overview of the Uterine Leiomyoma (Uterine Fibroids)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Uterine Leiomyoma (Uterine Fibroids) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Uterine Leiomyoma (Uterine Fibroids) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uterine Leiomyoma (Uterine Fibroids) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Uterine Leiomyoma (Uterine Fibroids) Overview 7
Therapeutics Development 8
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Overview 8
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis 9
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Development by Companies 10
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Investigation by Universities/Institutes 11
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Uterine Leiomyoma (Uterine Fibroids) - Products under Development by Companies 15
Uterine Leiomyoma (Uterine Fibroids) - Products under Investigation by Universities/Institutes 16
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development 17
Neurocrine Biosciences, Inc. 17
Novartis AG 18
Dongkook Pharmaceutical Co., Ltd. 19
HRA Pharma, SA 20
Evestra, Inc. 21
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 26
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ulipristal acetate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
LFA-102 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GnRH Antagonists - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Gonadotropin-Releasing Hormone Antagonists - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EVE-104 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EC-304 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
triptorelin pamoate biosimilar - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Non-Steroidal Progesterone Agonist - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Uterine Leiomyoma (Uterine Fibroids) - Recent Pipeline Updates 43
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects 46
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products 47
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones 48
Featured News & Press Releases 48
Mar 27, 2013: Neurocrine Biosciences Initiates Phase IIb Study Of Elagolix For Treatment Of Uterine Fibroids 48
Feb 28, 2013: Repros Announces FDA Grants End Of Phase II Meeting To Discuss Proellex-V Phase III Study Design 48
Jan 03, 2013: Repros Reports Positive Topline Results From Phase II Study Of Proellex-V For Treatment Of Uterine Fibroids 48
Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 50
Jul 23, 2012: Repros's Proellex-V Shows Consistent Efficacy In Phase II Study Of Uterine Fibroids 50
Apr 30, 2012: Repros's Proellex-V Clears Hurdle In Uterine Fibroid Program 51
Mar 12, 2012: Watson Initiates US Phase III Clinical Trial Of Esmya 52
Feb 27, 2012: HRA Pharma's Esmya Receives European Commission Marketing Authorization For Pre-Operative Treatment Of Uterine Fibroids 53
Feb 02, 2012: PregLem Announces Full Results Of PEARL I And II Studies Of Esmya Published In New England Journal Of Medicine 54
Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59
List of Tables
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2014 8
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Neurocrine Biosciences, Inc., H1 2014 17
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Novartis AG, H1 2014 18
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2014 19
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by HRA Pharma, SA, H1 2014 20
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Evestra, Inc., H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 25
Number of Products by Stage and Mechanism of Action, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 30
Number of Products by Stage and Molecule Type, H1 2014 32
Uterine Leiomyoma (Uterine Fibroids) Therapeutics - Recent Pipeline Updates, H1 2014 43
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2014 46
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2014 47
List of Figures
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2014 8
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 26
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 27
Number of Products by Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 30
Number of Products by Top 10 Molecule Type, H1 2014 31
Number of Products by Stage and Top 10 Molecule Type, H1 2014 32
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Uterine Leiomyoma (Uterine Fibroids) Overview 7
Therapeutics Development 8
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Overview 8
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis 9
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Development by Companies 10
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Investigation by Universities/Institutes 11
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Uterine Leiomyoma (Uterine Fibroids) - Products under Development by Companies 15
Uterine Leiomyoma (Uterine Fibroids) - Products under Investigation by Universities/Institutes 16
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development 17
Neurocrine Biosciences, Inc. 17
Novartis AG 18
Dongkook Pharmaceutical Co., Ltd. 19
HRA Pharma, SA 20
Evestra, Inc. 21
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 26
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ulipristal acetate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
LFA-102 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GnRH Antagonists - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Gonadotropin-Releasing Hormone Antagonists - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EVE-104 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EC-304 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
triptorelin pamoate biosimilar - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Non-Steroidal Progesterone Agonist - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Uterine Leiomyoma (Uterine Fibroids) - Recent Pipeline Updates 43
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects 46
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products 47
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones 48
Featured News & Press Releases 48
Mar 27, 2013: Neurocrine Biosciences Initiates Phase IIb Study Of Elagolix For Treatment Of Uterine Fibroids 48
Feb 28, 2013: Repros Announces FDA Grants End Of Phase II Meeting To Discuss Proellex-V Phase III Study Design 48
Jan 03, 2013: Repros Reports Positive Topline Results From Phase II Study Of Proellex-V For Treatment Of Uterine Fibroids 48
Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 50
Jul 23, 2012: Repros's Proellex-V Shows Consistent Efficacy In Phase II Study Of Uterine Fibroids 50
Apr 30, 2012: Repros's Proellex-V Clears Hurdle In Uterine Fibroid Program 51
Mar 12, 2012: Watson Initiates US Phase III Clinical Trial Of Esmya 52
Feb 27, 2012: HRA Pharma's Esmya Receives European Commission Marketing Authorization For Pre-Operative Treatment Of Uterine Fibroids 53
Feb 02, 2012: PregLem Announces Full Results Of PEARL I And II Studies Of Esmya Published In New England Journal Of Medicine 54
Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59
List of Tables
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2014 8
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Neurocrine Biosciences, Inc., H1 2014 17
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Novartis AG, H1 2014 18
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2014 19
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by HRA Pharma, SA, H1 2014 20
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Evestra, Inc., H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 25
Number of Products by Stage and Mechanism of Action, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 30
Number of Products by Stage and Molecule Type, H1 2014 32
Uterine Leiomyoma (Uterine Fibroids) Therapeutics - Recent Pipeline Updates, H1 2014 43
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2014 46
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2014 47
List of Figures
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2014 8
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 26
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 27
Number of Products by Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 30
Number of Products by Top 10 Molecule Type, H1 2014 31
Number of Products by Stage and Top 10 Molecule Type, H1 2014 32
